To establish a proof-of-concept that CAR modification of Vγ9Vδ2 T cells can enhance their anti-myeloma activity, we used a non-integrating, mRNA electroporation technology to express anti-BCMA CAR in ex vivo expanded Vγ9Vδ2 T cells, which generated short-lived CAR-expressing cells. Here, TNFRSF17 is linked to plasma cell myeloma.